InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,985.38
(
0.02%
)
US TECH 100
20,504.80
(
0.07%
)
Dow Jones
43,958.19
(
0.11%
)
Brent Oil
72.47
(
0.83%
)
Bitcoin
90,995.28
(
0.48%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

kris_kade

Send PM Follow Ignore
Followers 22
Posts 1671
Boards Moderated 0
Alias Born 12/12/2006

kris_kade

Re: None

Sunday, 11/09/2008 2:11:33 PM

Sunday, November 09, 2008 2:11:33 PM

Post# of 19309
A leaf from the past...LEO could very well be in the same situation for DIC trials..

Bayer shelves drug produced from transgenic sheep. (Recombinant Proteins).
By Scott, Alex
Publication: Chemical Week
Date: Wednesday, July 16 2003

Bayer says it has shelved commercialization of its recombinant protein drug Alpha-1 Antitrypsin (recAAT) developed to treat lung disorders. PPL Therapeutics (Roslin, U.K.), which was to have manufactured the drug for Bayer using transgenic sheep, says it will shed up to 90% of its total staff, or about 130 positions, as a result of Bayer's withdrawal from the project.

Bayer says it cancelled the deal because of rising financial risks associated with the drug's clinical phase II trials, which FDA has asked to be repeated in parts because of a high drop out rate of trial
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up